Dr. Reddy's introduced wearable device for migraine management in India
Dr. Reddy’s Laboratories has recently launched Nerivio, a wearable therapy device that has been approved by the US Food and Drug Administration (USFDA) for the drug-free management of migraine. This is a significant development as migraine is a global health challenge, affecting approximately 30 percent of adults who suffer from it for 15 or more days per month, impacting around 1.7 to 4 percent of the population. Migraines are known to have a disproportionate impact on women, who make up approximately 60 percent of the 213 million migraine sufferers in India alone.
Nerivio is a non-invasive device that requires a prescription and is intended for the treatment of migraines. It can be used both acutely and preventively by adults and adolescents aged 12 years and above. The device is to be worn on the upper arm and should be used within 60 minutes of the onset of headache for acute treatment, or every alternate day to prevent migraines. The device uses a Remote Electrical Neuromodulation (REN) mechanism to activate conditioned pain modulation by stimulating nerve endings. This process initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects the original source of migraine pain in the head.
"Nerivio is a USFDA-approved, drug-free, noninvasive, first-of-its-kind product for migraine in India and offers a favourable safety profile. We believe this product meets a genuine unmet clinical need among migraine patients", said M. V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's, in a statement.
"The roll-out of Nerivio marks our entry into digital therapeutics. It is an area that is seeing increasing adoption by physicians as well as patients due to its potential to reduce pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases", he added.
Nerivio is clinically proven to be safe and effective. It is a suitable option for a wide range of patients, including those who prefer drug-free treatments, individuals with contraindications to medications or poor medication tolerance, sensitive populations such as adolescents and women of vulnerable age groups, and patients at risk of medication overuse headache.
Studies show that Nerivio is safe and well tolerated with no systemic side effects or concern for medication overuse. It has also proven efficacy in treating associated symptoms of migraine such as nausea, vomiting etc. Dr. Reddy's also recently signed an exclusive agreement for the commercial marketing and distribution of Nerivio in Germany, Austria, Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Spain, Sweden, Switzerland and the UK.
Nerivio is a non-invasive device that requires a prescription and is intended for the treatment of migraines. It can be used both acutely and preventively by adults and adolescents aged 12 years and above. The device is to be worn on the upper arm and should be used within 60 minutes of the onset of headache for acute treatment, or every alternate day to prevent migraines. The device uses a Remote Electrical Neuromodulation (REN) mechanism to activate conditioned pain modulation by stimulating nerve endings. This process initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects the original source of migraine pain in the head.
"Nerivio is a USFDA-approved, drug-free, noninvasive, first-of-its-kind product for migraine in India and offers a favourable safety profile. We believe this product meets a genuine unmet clinical need among migraine patients", said M. V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's, in a statement.
"The roll-out of Nerivio marks our entry into digital therapeutics. It is an area that is seeing increasing adoption by physicians as well as patients due to its potential to reduce pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases", he added.
Nerivio is clinically proven to be safe and effective. It is a suitable option for a wide range of patients, including those who prefer drug-free treatments, individuals with contraindications to medications or poor medication tolerance, sensitive populations such as adolescents and women of vulnerable age groups, and patients at risk of medication overuse headache.
Studies show that Nerivio is safe and well tolerated with no systemic side effects or concern for medication overuse. It has also proven efficacy in treating associated symptoms of migraine such as nausea, vomiting etc. Dr. Reddy's also recently signed an exclusive agreement for the commercial marketing and distribution of Nerivio in Germany, Austria, Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Spain, Sweden, Switzerland and the UK.
